Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals

Novo Nordisk (NVO) is rated a BUY as business fundamentals are recovering faster than the stock, led by oral Wegovy’s historic U.S. launch. Oral Wegovy has generated 3+ million U.S. prescriptions in five months, with ~80% coming from GLP-1–naïve patients, expanding the obesity market. Management raised 2026 guidance on stronger-than-expected GLP-1 sales and international growth, and the note suggests further upward revisions are likely.

Analysis

Near term, the market is likely still underestimating how much of the obesity franchise is becoming a breadth story rather than just a unit-growth story. A credible oral option reduces initiation friction, broadens prescriber adoption, and can pull in patients who would never start an injectable, which matters more for lifetime value than first-fill optics. The main beneficiary is NVO; the second-order loser is the ecosystem built around supply-constrained, cash-pay semaglutide access, where branded convenience and perceived legitimacy can compress traffic and pricing power.

Over the next 1-3 months, the key variable is not demand but persistence: if refill behavior and payer recognition remain strong, this becomes a multi-quarter estimate reset rather than a one-off launch pop. That would likely force multiple expansion because investors can start modeling a larger addressable market with less reliance on international growth. By contrast, if early usage is mostly novelty-driven or concentrated in lower-commitment patients, the stock can give back quickly once the initial script surge normalizes.

The contrarian risk is that the launch is being treated as purely additive when it may partially cannibalize higher-margin injectable demand or face faster payer pushback as utilization scales. The biggest falsifier is a slowdown in prescription momentum or a guidance step-down after the first few post-launch quarters, especially if compounding enforcement does not tighten as expected. Structurally, though, this looks like a class-defining distribution advantage that should pressure smaller telehealth and compounding intermediaries first, then force LLY to defend share with its own convenience narrative.

Key Decisions for Investors

• Long NVO on weakness over the next 2-6 weeks; use any post-rally consolidation to build exposure for a 3-6 month re-rating trade tied to estimate revisions and persistence data.
• Pair trade: long NVO / short HIMS for 1-3 months to express branded-GLP-1 share gain versus compounding-dependent consumer demand; thesis breaks if compounding remains structurally protected or HIMS proves it can reprice mix upward.
• If seeking cleaner beta isolation, long NVO / short XBI as a tactical hedge around obesity-launch data, with upside driven by idiosyncratic commercial execution rather than broad biotech sentiment.
• Set a downside alert on NVO if the stock underperforms after the next quarterly update despite another guide raise; that would signal the market is assigning the launch to transitory demand rather than durable TAM expansion.
• Watch for payer and refill data over the next 1-2 quarters; if persistence disappoints, trim exposure quickly because the investment case shifts from structural to event-driven.